医学
围手术期
胰腺癌
化疗
危险系数
比例危险模型
胰腺切除术
癌症
单变量分析
内科学
外科
肿瘤科
多元分析
胃肠病学
胰腺
置信区间
作者
SHINNOSUKE KAWAHARA,Toru Aoyama,Masaaki Murakawa,Rei Kanemoto,Daishi Takahashi,Yuto Kamioka,ITARU HASHIMOTO,Yukio Maezawa,Satoshi Kobayashi,Makoto Ueno,Naoto Yamamoto,Takashi Oshima,Norio Yukawa,Yasushi Rino,Aya Saito,SOICHIRO MORINAGA
标识
DOI:10.21873/anticanres.16970
摘要
Background/Aim: The prognostic nutritional index (PNI) is used as a marker to evaluate the nutritional and immunological status of patients with various cancers. This study aimed to investigate whether preoperative PNI is a prognostic factor in patients with pancreatic cancer who underwent perioperative adjuvant chemotherapy and surgical resection. Patients and Methods: We retrospectively enrolled 232 pancreatic cancer patients who underwent surgical resection with perioperative adjuvant chemotherapy between January 2013 and December 2022. Overall survival (OS) and relapse-free survival (RFS) rates were calculated using the Kaplan–Meier method. Univariate and multivariate analyses were performed using the Cox proportional hazards regression models. Results: The optimal cutoff value for the preoperative PNI was 44.3 in the present study. PNI <44.3 was associated with older age (p<0.001) and affected the clinical course of postoperative adjuvant chemotherapy. The PNI <44.3 had an important influence on the decreased OS (25.1 vs. 39.0 months) and RFS (13.1 vs. 22.8 months). In univariate and multivariate analyses, the preoperative PNI was an independent prognostic factor for OS [hazard ratio (HR)=1.682, 95% confidence interval (CI)=1.059-2.673, p=0.028] and RFS (HR=1.559, 95% CI=1.037-2.344, p=0.033). Conclusion: Preoperative PNI is a prognostic factor for both OS and RFS in patients with pancreatic cancer who underwent perioperative adjuvant chemotherapy and surgical resection. This study suggests that a low PNI may cause a lack of full-dose adjuvant chemotherapy, leading to recurrence and resulting in a poor prognosis for surgical pancreatic cancer patients treated with perioperative adjuvant chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI